•• Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217–22. https://doi.org/10.2991/jegh.k.191008.001This paper provides the most recent data regarding cancer statistics globally.

Article  PubMed  PubMed Central  Google Scholar 

Organization WH. Global Health Estimates 2015: disease burden by cause, age, sex, by country and by region, 2000–2015. Geneva. 2016;2018.

•• Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020;6:1063–75. https://doi.org/10.1200/GO.20.00122This is a report on cancer statistics of India highlighting tobacco use associated cancer.

Article  PubMed  Google Scholar 

Poojari R, Sawant AV, Kini S, Srivastava R, Panda D. Antihepatoma activity of multifunctional polymeric nanoparticles via inhibition of microtubules and tyrosine kinases. Nanomedicine (London). 2020;15(4):381–96. https://doi.org/10.2217/nnm-2019-0349.

CAS  Article  Google Scholar 

Badekila AK, Kini S, Jaiswal AK. Fabrication techniques of biomimetic scaffolds in three-dimensional cell culture: a review. J Cell Physiol. 2020;236:1–22. https://doi.org/10.1002/jcp.29935.

CAS  Article  Google Scholar 

Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2020;18:1–23. https://doi.org/10.1080/17425247.2021.1828339.

CAS  Article  Google Scholar 

Jin K-T, Lu Z-B, Chen J-Y, Liu Y-Y, Lan H-R, Dong H-Y, et al. Recent trends in nanocarrier-based targeted chemotherapy: selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. J Nanomater. 2020;2020:1–14.

Article  Google Scholar 

•• Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017, 6(1):44. https://doi.org/10.1186/s40169-017-0175-0This review provides insight on different types of nanoformulations and their applications.

•• Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–34 This is a comprehensive review on Doxil®, first nanoformulation approved for cancer therapy.

CAS  Article  Google Scholar 

•• Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99 This is a comprehensive review on Abraxane, one of the first nanoformulation approved for cancer therapy.

CAS  PubMed  PubMed Central  Google Scholar 

Buabeid MA, Arafa EA, Murtaza G. Emerging prospects for nanoparticle-enabled cancer immunotherapy. J Immunol Res. 2020;2020:9624532–11. https://doi.org/10.1155/2020/9624532.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bhardwaj V, Kaushik A, Khatib ZM, Nair M, McGoron AJ. Recalcitrant issues and new frontiers in nano-pharmacology. Front Pharmacol. 2019;10:1369. https://doi.org/10.3389/fphar.2019.01369.

Article  PubMed  PubMed Central  Google Scholar 

Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed Nov 18 2020.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

Article  Google Scholar 

Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol. 2017;27(1):3–10. https://doi.org/10.1016/j.semradonc.2016.08.002.

Article  PubMed  Google Scholar 

Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, et al. The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomark Prev. 2014;23(11):2303–10. https://doi.org/10.1158/1055-9965.EPI-13-0568.

Article  Google Scholar 

McClure TBS, Sandhu JS, Schlegel PN, Colt JJ. Prostate cancer. In: Encyclopedia of Endocrine Diseases Elsevier. 2018.

•• Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007;7(10):3065–70. https://doi.org/10.1021/nl071546nThis article reports the application of QD-aptamer-doxorubicin conjugate designed specifically to target PSMA with bioimaging, biosensing and therapeutic application.

CAS  Article  PubMed  Google Scholar 

Lee JY, Kim JS, Cho HJ, Kim DD. Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery. Int J Nanomedicine. 2014;9:2803–13. https://doi.org/10.2147/IJN.S62806.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Pilot study of AuroLase(tm) therapy in refractory and/or recurrent tumors of the head and neck - full text view - ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT00848042. Accessed Nov 18 2020.

A phase I safety study of a cancer vaccine to treat HLA-A2 positive advanced stage ovarian, breast and prostate cancer - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/study/NCT01095848. Accessed Nov 18 2020.

A study evaluating MM-310 in patients with solid tumors - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03076372. Accessed Nov 18 2020.

• Rastinehad AR, Anastos H, Wajswol E, Winoker JS, Sfakianos JP, Doppalapudi SK, et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proc Natl Acad Sci U S A. 2019;116(37):18590–6. https://doi.org/10.1073/pnas.1906929116This paper explores application of gold nanoparticles photothermal cancer therapy specifically treating the prostate cancer.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Nanospectra biosciences announces four additional prestigious trial sites for pivotal AuroLase study https://www.prnewswire.com/news-releases/nanospectra-biosciences-announces-four-additional-prestigious-trial-sites-for-pivotal-aurolase-study-301105402.html. Accessed Nov 18 2020.

Trial of NanoPac® focal therapy in subjects with prostate cancer - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/study/NCT03077659. Accessed Nov 2018 2020.

Vicente-Ruiz S, Serrano-Martí A, Armiñán A, Vicent MJ. Nanomedicine for the treatment of advanced prostate cancer. Advanced Therapeutics. 2020;2000136.

Karkada M, Quinton T, Blackman R, Mansour M. Tumor inhibition by DepoVax-based cancer vaccine is accompanied by reduced regulatory/suppressor cell proliferation and tumor infiltration. ISRN Oncol. 2013;2013.

Hrytsenko O, Weir GM, Stanford MM. Combination of a DepoVax™ peptide vaccine with a lentivector vaccine induces strong antigen-specific immune responses and provides effective tumor control in murine models. Am Assoc Immnol; 2018.

Google Scholar 

Siegel R, Miller K. Jemal A (2020) cancer statistics. CA Cancer J Clin. 2020;70(1):7–30.

Article  Google Scholar 

•• Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. https://doi.org/10.1016/S0140-6736(16)30958-8.It is a comprehensive review discusses conventional as well as novel targeted therapies for lung cancer treatment.

CAS  Article  PubMed  Google Scholar 

Basumallik N, Agarwal M. Small cell lung cancer. Treasure Island (FL): StatPearls; 2020.

Google Scholar 

Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60(8):863–75. https://doi.org/10.1016/j.addr.2007.11.006.

CAS  Article  PubMed  Google Scholar 

Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012;7(4):e34833. https://doi.org/10.1371/journal.pone.0034833.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–35. https://doi.org/10.1093/annonc/mdt412.

CAS  Article  PubMed  Google Scholar 

•• van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386–96. https://doi.org/10.1016/S1470-2045(17)30621-6A phase I clinical trial evaluted the safety dosage, activity and associated side-effects of a novel nanomedicine derived from microRNA loaded minicells for treating pleural mesothelioma.

Article  PubMed  Google Scholar 

Yurkovetskiy AV, Hiller A, Syed S, Yin M, Lu XM, Fischman AJ, et al. Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Mol Pharm. 2004;1(5):375–82. https://doi.org/10.1021/mp0499306.

CAS  Article  PubMed  PubMed Central  Google Scholar 

MacKenzie M, Hirte H, Siu L, Gelmon K, Ptaszynski M, Fisher B, et al. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol. 2004;15(4):665–70.

CAS  Article  Google Scholar 

Safety and pharmacokinetics of escalating doses of DNIB0600A in participants with non-small cell lung cancer (NSCLC) and platinum resistant ovarian cancer - full text view - ClinicalTrials.gov. https://ClinicalTrials.gov/show/NCT01363947. Accessed Nov 18 2020.

Chen H, Dy G, Groman A, Farrell E, Miller A, Bushunow P, et al. MA 01.06 A phase II study of etirinotecan pegol (NKTR-102) in patients with chemotherapy-resistant small cell lung cancer. J Thorac Oncol. 2017;12(11):S1800–S1.

Article  Google Scholar 

•• Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3157–63. https://doi.org/10.1158/1078-0432.CCR-15-2548This study describes the safety aspects of nanoparticle-drug conjugate BIND-014 containing docetaxel used for treating advanced solid tumors.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, et al. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Ann Oncol. 2016;27(8):1579–85. https://doi.org/10.1093/annonc/mdw188.

CAS  Article  PubMed  PubMed Central  Google Scholar 

• Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, et al. Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors. Clin Cancer Res. 2018;24(1):43–51. https://doi.org/10.1158/1078-0432.CCR-17-1114A cohort phase Ib/II study showed a well tolerability against cisplatin nanoformulation in combination with gemcitabine in advanced solid tumors with no clinical neuro,oto and nephrotoxicity.

CAS  Article  PubMed  Google Scholar 

Numico G, Castiglione F, Granetto C, Garrone O, Mariani G, Di Costanzo G, et al. Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer. 2002;35(1):59–64.

Article  Google Scholar 

Study of irinotecan liposome injection (ONIVYDE®) in patients with small cell lung cancer (RESILIENT) - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03088813. Accessed Nov 18 2020.

A trial of paclitaxel (Genexol®) and cisplatin versus paclitaxel loaded polymeric micelle (Genexol-PM®) and cisplatin in advanced non small cell lung cancer full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01023347. Accessed Nov 18 2020.

Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10(11):3708–16. https://doi.org/10.1158/1078-0432.CCR-03-0655.

CAS  Article  PubMed  Google Scholar 

Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P, et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8):1263–8.

CAS  Article  Google Scholar 

Chen H, Dy G, Groman A, Brady W, Jamshed S, Bushunow P, et al. P1. 07-001 A phase II study of etirinotecan pegol (NKTR-102), a topoisomerase-I inhibitor polymer conjugate, in small cell lung cancer: topic: drug treatment alone and in combination with radiotherapy. J Thorac Oncol. 2017;12(1):S695–S6.

Article  Google Scholar 

Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, et al. Phase 1/2 Study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. Clin Lung Cancer. 2017;18(1):68–76 e2. https://doi.org/10.1016/j.cllc.2016.09.002.

CAS  Article